| Code | CSB-RA010509MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TTX-080, targeting human leukocyte antigen G (HLA-G), a non-classical major histocompatibility complex class I molecule. HLA-G functions as an immune checkpoint protein that delivers inhibitory signals to immune cells, promoting immune tolerance through interactions with receptors including ILT2, ILT4, and KIR2DL4. Unlike classical HLA molecules, HLA-G exhibits restricted tissue expression under normal conditions but becomes aberrantly expressed in various malignancies, where it facilitates tumor immune evasion by suppressing natural killer cells, cytotoxic T lymphocytes, and antigen-presenting cells. Elevated HLA-G expression correlates with poor prognosis in multiple cancer types, including renal cell carcinoma, melanoma, and hematologic malignancies.
TTX-080 represents a clinical-stage therapeutic antibody designed to block HLA-G-mediated immunosuppression in the tumor microenvironment. This biosimilar provides researchers with a valuable tool for investigating HLA-G biology, immune checkpoint mechanisms, and tumor immunology. It supports studies examining immune evasion pathways, therapeutic antibody development, and combination immunotherapy strategies targeting the HLA-G axis in oncology research.
There are currently no reviews for this product.